320 related articles for article (PubMed ID: 15448666)
41. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
42. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
43. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
44. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
45. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
46. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
47. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
[TBL] [Abstract][Full Text] [Related]
48. [Salvage therapy in relapsed or refractory malignant lymphoma].
Kashimura T; Murohashi I
Nihon Rinsho; 2000 Mar; 58(3):699-703. PubMed ID: 10741149
[TBL] [Abstract][Full Text] [Related]
49. Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experience.
Michallet AS; Chelghoum Y; Thiebaut A; Le QH; Prebet T; Tavernier E; Antal D; Nicolini F; Troncy J; Elhamri M; Michallet M; Thomas X
Hematology; 2006 Jun; 11(3):157-64. PubMed ID: 17325955
[TBL] [Abstract][Full Text] [Related]
50. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
51. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
52. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
[TBL] [Abstract][Full Text] [Related]
53. Autologous bone marrow transplantation as consolidation therapy in newly diagnosed non-Hodgkin's lymphoma: long-term outcome.
Montuoro A; Lalle M; Ingletto D
Int J Oncol; 2000 Oct; 17(4):771-5. PubMed ID: 10995890
[TBL] [Abstract][Full Text] [Related]
54. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
55. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
56. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.
Ladetto M; Zallio F; Vallet S; Ricca I; Cuttica A; Caracciolo D; Corradini P; Astolfi M; Sametti S; Volpato F; Bondesan P; Vitolo U; Boccadoro M; Pileri A; Gianni AM; Tarella C
Leukemia; 2001 Dec; 15(12):1941-9. PubMed ID: 11753616
[TBL] [Abstract][Full Text] [Related]
57. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Stone RM; Neuberg D; Soiffer R; Takvorian T; Whelan M; Rabinowe SN; Aster JC; Leavitt P; Mauch P; Freedman AS
J Clin Oncol; 1994 Dec; 12(12):2535-42. PubMed ID: 7989927
[TBL] [Abstract][Full Text] [Related]
58. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up.
Vose JM; Bierman PJ; Anderson JR; Kessinger A; Pierson J; Nelson J; Frappier B; Schmit-Pokorny K; Weisenburger DD; Armitage JO
Blood; 1992 Oct; 80(8):2142-8. PubMed ID: 1356515
[TBL] [Abstract][Full Text] [Related]
59. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma.
Kim JW; Lee HJ; Yi HG; Kim BS; Bang SM; Kim JS; Kim I; Yoon SS; Lee JS; Kim CS; Park S; Kim BK
Am J Hematol; 2012 May; 87(5):479-83. PubMed ID: 22388671
[TBL] [Abstract][Full Text] [Related]
60. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.
Freedman AS; Takvorian T; Anderson KC; Mauch P; Rabinowe SN; Blake K; Yeap B; Soiffer R; Coral F; Heflin L
J Clin Oncol; 1990 May; 8(5):784-91. PubMed ID: 2332768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
